ABSTRACT: Epigenetic inactivation of genes that are crucial for the control of normal cell growth is a hallmark of cancer cells. Epigenetic modifications of the DNA do not alter the nucleotide sequence instead they involve the regulation of gene transcription and DNA methylation. Hypermethylation or histone deacetylation, which is within the promoter of a tumor suppressor gene, leads to the silencing as well as a deletion or a mutation of that gene. Cancer cells often show aberrant methylation and the frequency of aberrations increases is seen with the progression of disease. Hypermethylation events can occur early in tumorogenesis, involving the disruption of pathways that may predispose cells to malignant transformation. Epigenetic modification such as DNA methylation can be exploited for clinical purposes in cancer patients, first using hypermethylation as a molecular biomarker of cancer cells and second, epigenetic changes which are potentially reversible.
INTRODUCTION ᴪ
Epigenetics refers to mitotically and/or meiotically heritable variations in gene expression that are not caused by changes in DNA sequence. Epigenetic mechanisms regulate all biological processes from conception to death, including genome reprogramming during early embryogenesis and gametogenesis, cell differentiation and maintenance of a committed lineage. Key epigenetic players are DNA methylation and histone post-translational modifications, which interplay with each other, with regulatory proteins and with non-coding RNAs, to remodel chromatin into domains such as euchromatin, constitutive or facultative heterochromatin and to achieve nuclear compartmentalization 1 . Epigenetics is one of the key areas of future research that can elucidate how genomes work. It combines genetics and the environment to address complex biological systems such as the plasticity of our genome. While all nucleated human cells carry the same genome, they express different genes at different times. Much of this is governed by epigenetic changes resulting in 
DNA METHYLATION
Epigenetic modifications of the DNA do not alter the sequence code instead they involve the regulation of gene transcription, DNA methylation 6 . In mammals, the major target for DNA methylation is a cytosine located next to a guanine (5'-CpG-3') found in CpG islands 7 . Methylation patterns are transmitted to the next generations during cell division. During embryonic development, currently undefined regulatory mechanisms allow rapid demethylation in very early stages followed by reestablishment of methylation patterns after implantation 8 . DNA methyltransferases (DNMTs) transfer the methyl group that is provided by Sadenosylmethionine to the 5'-carbon of a cytosine, there are only four types of DNMTs known of which three active DNA methyltransferases have been identified in mammals. . Second and probably more common mechanism involves proteins that detect methylated DNA through methyl CpG-binding domains (MBDs) 
EPIGENOMICS AND CANCER
Studies by the Human Epigenome Project (HEP) studies now highlight the importance and complexity of cytosine DNA methylation in tissuespecific regulation of gene expression 18 . The cancer gene functions can be classified into six essential alterations in cell physiology, including selfsufficiency in growth signals, insensitivity to growth inhibitory signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis 19 . In human cancer, the DNA methylation aberrations observed can be considered as falling into one of two categories: transcriptional silencing of tumor suppressor genes by CpG island promoter hypermethylation and a massive global genomic hypomethylation. Global DNA hypomethylation has been reported in almost every human malignancy 20 . This hypomethylation can be confirmed by HPLC by measurement of 5'-methyl cytosine level.the level was found to be decreased when as compared to normal tissue controls 21 Hypomethylation of the tumor genome could be verified by assays determining demethylation in specific sequences. Interestingly, the majority of hypomethylation events occur in repetitive elements localized in satellite sequences or centromeric regions 22 . While hypomethylation of repetitive elements is a common finding in human malignancies, gene-associated CpG islands are the targets of hypermethylation. Hypermethylation was initially discovered as a novel mechanism of tumor suppressor gene silencing in numerous genes that had been identified as targets for genetic alterations. Large-scale methylation studies on cancer genes became possible with the introduction of sodium bisulfite treatment of genomic DNA that results in a conversion of unmethylated cytosines to uracils but leaves methylcytosines unaltered/unmodified. 
27
. Epigenetic inactivation of genes that are crucial for the control of normal cell growth is a hallmark of cancer cells. These epigenetic mechanisms include crosstalk between DNA methylation, histone modification and other components of chromatin higher-order structure, and lead to the regulation of gene transcription. ?of genes epigenetically inactivated can result in the suppression of tumour growth or sensitization to other anticancer therapies. Small molecules that reverse epigenetic inactivation are now undergoing clinical trials in cancer patients. This, together with epigenomic analysis of chromatin alterations such as DNA methylation and histone acetylation, opens up the potential both to define epigenetic patterns of gene inactivation in tumours and to use drugs that target epigenetic silencing.. Cancer stem cells (CSCs) are thought to sustain cancer progression, metastasis and recurrence after therapy. There is in vitro and in vivo evidence supporting the idea that CSCs are highly chemoresistant. Epigenetic gene regulation is crucial for both stem cell biology and chemoresistance. CSC epigenomic profiling helps to dissect specific chemoresistance pathways, and have a significant clinical impact for patient stratification and rational design of therapeutic regimens 29 . The epigenome is little unusual since/for the fact that many changes may appear to be tissueor disease specific and perhaps less diverse and chaotic than those seen in cancer development. These epigenetic profiles, perhaps accessible through free DNA in body fluids, could be used as tools for diagnostics or as biomarkers once they have been mapped and catalogued.. An altered pattern of epigenetic modifications is central to many common human diseases, including cancer. Extensive studies have explored the mosaic patterns of DNA methylation and histone modification in cancer cells on a gene-by-gene basis.
30, 31 . Epigenetic silencing in cancer cells is mediated by at least two distinct histone modifications. Polycomb-based histone H3lysine27 trimethylation (H3K27triM) and H3K9 dimethylation.suggests mechanism of tumorsuppressor gene silencing in cancer is potentially independent of promoter DNA methylation
32,33
.
RECENT ADVANCEMENT AND FUTURE IMPLICATIONS
The discovery of 5methylcytosine, so called 5 th base modification has immensely increased the filed of epigenomics /genetics 34, 35 . Prior to the advent of the new sequencing technologies, the potential for epigenomics in medicine was already widely recognized 36, 37 . Its role in cancer development, aging, gene regulation, embryogenesis and the modulation of genetic factors has been well described 36, 38 . The most immediate impact of the new sequencing technologies has been on so-called 'ChIP-seq' experiments, where the locations of histone proteins can be mapped to the genome identifying epigenetic control of chromatin structure and gene expression 39 . These proteins leave a footprint on the DNA that protects it from shearing during sample preparation. This is a simpler experiment using the same genomic fragmentation and sequence remapping techniques used for mutation detection in sequencing experiments 40 . The significance of the identified regions can then be determined. This technique replaces an array-based method, ChIP on ChIP, and is generally considered hypothesis-free, more sensitive, and thus superior. Detecting the modification of cytosine, and its location on DNA from a given sample can currently be performed using any sequencing technique based on bi-sulfite treatment of DNA. Earlier embodiments required pulling down a subset of the genome to be analyzed using an antibody precipitation method known as 'methylated DNA immunoprecipitation' (MeDIP), often followed by an array based analysis 41 . Many other methylation site subsetting techniques have been described. Bi-sulfite treatment leaves 5-methylcytosine intact, but modifies cytosine (denoted as C) to a uracil analogue. During sequencing, by tghe use of technologies based on complementary synthesis or probe ligation, this is recognized as the base thymine (denoted T). A minor complication which might occur is remapping the resulting sequences to the genome in order to locate the site of the modifications. The other is the amount of DNA required for bi-sulfite Copyrighted © by Dr. Arun Kumar Agnihotri. All right reserved treatment, and any biases or artefacts this treatment may introduce
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. Nonetheless, genome-wide surveys of methylation have recently been performed using such techniques on secondgeneration sequencers. Stem cell chromatin control of gene expression, including relationships between histone modifications and DNA methylation, hold a key to understanding the origins of cancer epigenetic changes 30, 42 . DNA methylation can be exploited for clinical purposes in cancer patients as a molecular biomarker of cancer cells. Since the presence of CpG island hypermethylation of the tumor suppressor genes described is specific to transformed cells. Example: Presence of hypermethylation of the glutathione S-transferase P1 (GSTP1) gene in prostate cancer 43 . Hypermethylation could also be used as tool for detecting cancer cells in multiple biological fluids or even for monitoring hypermethylated promoter loci in serum DNA from cancer patients
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. Second, unlike genetic changes in cancer, epigenetic changes are potentially reversible. For years, in cultured cancer cell lines, we have been able to express genes that had been silenced by methylation by using DNA demethylating agents such as 5-aza-2-deoxycytidine, 5-azacitidine or zebularine 45, 46 . These two factors makes epigenomics a potential area for cancer research, diagnosis and treatment.
